Enterprise Europe Network

Spanish biotech company offers testing services for telomere diagnostics

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
BOES20190402001
Published
02/04/2019
Last update
19/05/2020
Expiration date
11/04/2021

Keywords

Partner keyword: 
Clinical Research, Trials
Cytology, Cancerology, Oncology
Diagnostics, Diagnosis
Environmental Medicine, Social Medicine, Sports Medicine
Medical Research
Diagnostic services
In-vitro diagnostics
Other diagnostic
Other medical/health related (not elsewhere classified)
Specialist medical practice activities
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
Founded in 2010, the Spanish biotech company is a world leader in telomere diagnostics for clinical use in oncology and preventive and personalized medicine. With headquarters in Madrid, (Spain) they are an industry-leading biotechnology company working to improve people’s health and lifestyle. The types of partnerships considered by the company include financial agreements, joint venture agreements and services agreements worldwide.

Description

Description: 

The analytical validation and the certification of the test under Clinical Laboratory Improvement Amendments (CLIA-88) and International Organization for Standardization (ISO-15189) were completed in June 2016 and all the critical aspects of the test are controlled and supervised accordingly. Moreover, their
laboratories had in situ reviews by regulators in 2017 and 2018 with reaccreditation and satisfactory results.

The company has applied for patents and is expecting to have CE (European Conformity) marking and the International Organization for Standardization (ISO-13485) certification.

The company is expecting accreditation from the European Medicines Agency (EMA) for the use of its test in prostate cancer screening in 2019 and approval in the U.S. through the Food and Drug Administration (FDA) as an In Vitro Diagnostic (IVD) with similar pathway for lung cancer screening to commence in 2020.

They also offer testing services to physicians and individuals, researchers and corporations across many industries and regions, developing the adoption of telomeres and telomerase activity as key health biomarkers, advancing towards better and longer lifespans.

The company is seeking partners in the field of diagnostic oncology for prostate and lung cancer companies from the pharma, biotech /life sciences and nutraceutical companies -for in vitro and in vivo testing and studies- as well as personalized and preventive medicine companies.

The types of partnerships considered are financial agreements, joint venture agreements and services agreements.

Advantages & innovations

Cooperation plus value: 
The Company is accredited with Clinical Laboratory Improvement Amendments (CLIA) and International Organization for Standardization (ISO) regulations, and their telomere analysis technology is focused on oncology diagnostics and prognostics. The strongest points of Telomere Analysis Technology and its quality assurance are based on the fine-tuning of the conditions required to optimize and guarantee: Accuracy; Precision Limit of Detection and Specificity. In addition, they have included a new, comprehensive data base reportable ranges and reference ranges. The company´s technology platform has the potential to become broadly applicable on a wide range of diseases, whenever the combination of disease specific Telomere-Associated Variables (TAV’s) can be combined with disease specific clinical data into a sharp cut-off algorithm for risk scoring of that disease (diagnosis or prognosis). Moreover, a EU Horizon 2020 research and innovation programme granted the Company with two-year studies involving over 6,000 patients to validate the Telomere-Associated Variables (TAV’s) as cancer biomarkers in prostate and lung cancer for screening and diagnosis and prognosis in leukemia.

Technical Specification or Expertise Sought

Cooperation sought: 
The company is seeking partners in the field of diagnostic oncology for prostate and lung cancer companies from the pharma, biotech /life sciences and nutraceutical companies -for in vitro and in vivo testing and studies- as well as personalized and preventive medicine companies. The types of partnerships considered are financial agreements, joint venture agreements and services agreements.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
The company is seeking companies in the fields of diagnostic oncology for prostate and lung cáncer from the pharma, biotech /life sciences and nutraceutical areas, as well as personalized and preventive medicine companies to establish service, financial or joint venture agreements.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,>500 MNE,SME 51-250,>500